Publication & Citation Trends
Publications
712 total
Abstract 3999: Pan-cancer prediction of response to immune checkpoint blockade from histopathology
Cited by 0
Semantic Scholar
DZ-1-artesunate conjugate induces mitochondria-mediated, reactive oxygen species-dependent apoptosis in colorectal cancer tumoroids
Cited by 0
Semantic Scholar
Pan-cancer prediction of tumor immune activation and response to immune checkpoint blockade from tumor transcriptomics and histopathology
Cited by 0
Semantic Scholar
Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study.
Cited by 14
Semantic Scholar
A phase 1b, open-label, safety, tolerability, and efficacy study of HC-7366 in combination with belzutifan in patients with advanced or metastatic renal cell carcinoma (NCT06234605).
Cited by 1
Semantic Scholar
Updated results from the phase 2 LITESPARK-003 study of belzutifan plus cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC).
Cited by 2
Semantic Scholar
LBA87 Phase II LITESPARK-003 study of belzutifan in combination with cabozantinib for advanced clear cell renal cell carcinoma (ccRCC) OA
Cited by 14
Semantic Scholar
1612P The impact of COVID-19 pandemic on distress level in cancer patients, a cross-sectional multicentric study OA
Cited by 1
Semantic Scholar
1611P Health-related quality of life, vaccine uptake and immune response among cancer patients undergoing treatment during the COVID-19 pandemic OA
Cited by 0
Semantic Scholar
Targeted therapies for renal cell carcinoma
Cited by 1
Semantic Scholar
Research Topics
Renal cell carcinoma treatment
(420)
Renal and related cancers
(161)
Cancer Genomics and Diagnostics
(150)
Cancer Immunotherapy and Biomarkers
(82)
Bladder and Urothelial Cancer Treatments
(73)
Affiliations
Université Claude Bernard Lyon 1
University of Southern California
Roche (Switzerland)
Texas Tech University
Cedars-Sinai Medical Center